Reetu Mukherji, MD, is a fellowship-trained medical oncologist. She specializes in management of gastrointestinal malignancies, including esophagus, stomach, small bowel, colon, rectum, anal, pancreatic, and hepatobiliary cancers. Dr. Mukherji leads the medical oncology department’s clinical and research focus on upper gastrointestinal malignancies, including esophageal and gastric cancers.
She earned her medical degree from Temple University School of Medicine and completed her residency at Thomas Jefferson University Hospital, both of which are located in Philadelphia. Dr. Mukherji completed a fellowship in hematology/oncology at MedStar Georgetown University Hospital.
Dr. Mukherji has published in several peer-reviewed journals, including Current Treatment Options in Oncology and Journal of Clinical Oncology, on the role of immunotherapies, applications of prognostic genomic biomarkers, and applications of liquid biopsies in the management of patients with gastrointestinal malignancies. She has also designed investigator-initiated clinical trials studying emerging blood-based biomarkers like circulating tumor DNA and testing novel therapies across gastrointestinal cancers. Her research includes collaboration with basic scientists to study circulating tumor cells from liquid biopsies.
She is a member of the American Society of Clinical Oncology, the American Society of Hematology, and the American Medical Association.
About MedStar Georgetown Cancer Institute
MedStar Georgetown is part of the MedStar Georgetown Cancer Institute, which combines medical expertise, the latest therapies, and research across MedStar Health. Our research engine, the Georgetown Lombardi Comprehensive Cancer Center, is the only National Cancer Institute-designated comprehensive cancer center in the Washington, D.C., region. This partnership means we provide access to cutting-edge clinical trials and the latest breakthroughs in cancer care.
Dr. Mukherji’s philosophy of care
Dr. Mukherji is committed to approaching each patient comprehensively and with respect. She understands a cancer diagnosis is life-changing for patients and values educating them on their complex disease and management strategies in order to make informed decisions together in their best interest. She strongly believes in the value of working collaboratively with patients, their support systems, and multi-disciplinary teams to deliver the highest level of care and support through their cancer diagnosis.
Clinical areas of focus
- Colorectal Malignancy
- Esophageal Cancer
- Pancreas Cancer
- Rectal Cancer
- Stomach Cancer
Conditions and procedures
Conditions I treat
- Abdominal Cancer
- Anal Cancer
- Appendiceal Cancer
- Bile Duct Mass
- Cancer During Pregnancy
- Cancer Pain
- Cancer Related Fatigue
- Cancer Survivor
- Colorectal Malignancy
- Cowden Syndrome
- Esophageal Cancer
- Gallbladder Cancer
- Gastroesophageal Junction Cancer
- Gastrointestinal (GI) Cancer
- Gastrointestinal (GI) Stromal Tumors
- Head And Neck Tumors
- Hereditary Cancer Risk
- Liver Cancer
- Liver Metastases
- Malignant Carcinoid Tumor Of Colon
- Pancreas Cancer
- Peutz Jeghers Syndrome
- Rectal Cancer
- Side Effects Of Cancer Treatment
- Small Intestine Cancer
- Stomach Cancer
Procedures I perform
- Adjuvant Chemotherapy
- Biological Targeted Therapy
- Bone Marrow Biopsy
- Cancer Chemotherapy
- Cancer Genomics
- Cancer Immunotherapy
- Colon Cancer Chemotherapy
- Colon Cancer Genomics
- Early Detection Of Cancer
- Esophageal Cancer Chemotherapy
- Gallbladder Cancer Chemotherapy
- Gallbladder Cancer Genomics
- Gastrointestinal (GI) Cancer Genomics
- Liver Cancer Genomics
- Pancreatic Cancer Chemotherapy
- Pancreatic Cancer Genomics
- Rectal Cancer Genomics
- Small Intestine Cancer Chemotherapy
- Stomach Cancer Chemotherapy
- Stomach Cancer Genomics
Distance from Change LocationEnter your Location
3800 Reservoir Road Northwest Washington, DC, 20007202-687-2200
MedStar Medical Group accepts most major health insurance plans. If you are uncertain as to whether your individual health insurance plan is accepted at MedStar Medical Group, please call your insurance company.
List of insurance plans we accept
- UnitedHealthcare Medicare Adv/Special Needs Plans
- UnitedHealthcare and AARP Medicare Complete Plans/ UHC Group Medicare Advantage Plans HMO, POS, PPO"
- United Student Resources
- United Healthcare Select Plus (POS)
- United Healthcare Select HMO - EPO/NPP
- United Healthcare Options (PPO) (includes Empire PPO, GEHA, Compass Rose)"
- United Healthcare Choice Plus
- United Healthcare Choice
- UHC Community Plan of MD
- Optimum Choice Preferred (POS) & OCI Direct (HMO)
- Mamsi Life & Health (Indem./PPO)
- M.D. IPA Preferred (POS)
- M.D. IPA (HMO)
- Tricare Prime
- Tricare for Life (Medicare Supplemental Plan)
- Private Health Care Systems (PHCS) (PPO)
- MedStar Select (MedStar Associates' Plan)
- MedStar Family Choice - Maryland Health Choice
- Medicare Fee for Service
- Kaiser Virginia Premier
- Kaiser PermanenteSelect-Added Choice
- Kaiser Permanente Signature-Added Choice
- Kaiser Permanente Signature
- Kaiser Permanente Select
- Kaiser Permanente Medicare Plus (Medicare Supplemental Plan)
- Kaiser Permanente Medicare Advantage Signature and Select (aka Senior Advantage)"
- Kaiser Permanente Flexible Choice POS
- Kaiser MD Medicaid MCO
- FIRST HEALTH
- First Health PPO
- Coventry of Delaware HMO/PPO
- Coventry Health Care of Virginia
- Coventry Health Care National Network PPO
- Great-West Healthcare POS/CIGNA
- CIGNA POS/Network POS
- CIGNA Indemnity
- POS OA & OA Plus
- Network OA
- CIGNA HMO Open Access (OA)
- CIGNA HMO & Network (HMO)
- Choice Fund PPO
- PPO and PPO Plus
- CIGNA EPO
- HealthyBlue PPO
- CFBSBC Blue Preferred PPO
- CFBCBS Maryland Indemnity or PPO
- CFBCBS Maryland Point of Service Plan (MPOS)
- CFBCBS Federal Employee Program (Std/Basic PPO/Blue Focus)
- CFBCBS EPO
- CFBCBS BlueChoice HMO
- CFBCBS Blue Choice Opt Out Plus Open Access (POS)
- Blue Choice Advantage & Healthy Blue (HMO, POS)"
- BlueChoice Open Access
- CFBCBS Blue Choice Opt Out Open Access
- CFBCBS (NCA) Indemnity
- Aetna Worker's Compensation Network
- Innovation Health: Indemnity
- Aetna Traditional Choice (PPO)
- Aetna Student Health Insurance
- Aetna Quality Point of Service (POS)
- Innovation Health: PPO
- Aetna Open Choice (PPO)
- Aetna Medicare Advantage HMO & PPO Plans
- Open POS II
- Innovation Health: Open POS Plus
- Choice POS & Choice POS II
- Aetna Managed Choice Open Access (POS)
- Innovation Health: POS Plus
- Aetna Managed Choice (POS)
- Open EPO Plus
- Opoen HMO Option
- Open HMO
- Innovation Health: POS
- Aetna HMO-Open Access/Select OA/HealthFund/Health Network Option OA
- Aetna Innovations: HMO & EPO Plus
- Select HMO/HealthFund/Health Network
- Aetna HMO
- Innovation Health: Open Network Only Plus
- Aetna Elect Choice/ Open Access (POS)
- Aetna Elect Choice/ EPO (Aetna Health Fund) Innovation Health: Network Only Plus
Board Certification: American Board of Internal Medicine, Internal Medicine
Board Certification: American Board of Internal Medicine, Hematology
Board Certification: American Board of Internal Medicine, Medical Oncology
Fellowship Program: MedStar Georgetown University Hospital (2022)
Residency Program: Sidney Kimmel Medical College (2019)
Medical School: Temple University School of Medicine (2016)
News and publications
- Mukherji R, Debnath D, Hartley M, Noel M. The Role of Immunotherapy in Pancreatic Cancer. Current Oncology. 2022; 29(10):6865-6892. doi: 10.3390/curroncol29100541
- Mukherji R, Yin C, Hammed R, Alqahtani A, Kulsekaran M, He A, Weinberg B, Marshall J, Hartley M, Noel M. The Current State of Molecular Profiling in Gastrointestinal Malignancies. Biology Direct. 2022; 18:15. doi.org/10.1186/s13062-022-00322-0
- Mukherji R, Alqahtani A, Winters H, Weinberg B. Use of Circulating Tumor DNA to Assess Minimal Residual Disease in Gastrointestinal Cancers. touchREVIEWS in Oncology & Haematology. 2022; 18(1): Online ahead of journal publication.
- Mukherji R, Weinberg B, Pedersen K. Immunotherapy for Colorectal Cancer. Hematology/Oncology Clinics of Northern America. 2022; 36(3): 603-626. doi 10.1016/j.hoc.2022.02.010.
- Mukherji R, Marshall J. Lessons Learned in Managing Patients with Colorectal Cancer During the Covid-19 Pandemic. Current Treatment Options in Oncology. 2021; 22(10):93. doi: 10.1007/s11864-021-00888-3.
- Mukherji R, Weinberg B. The Gut Microbiome and Potential Implications for Early-Onset Colorectal Cancer. Colorectal Cancer. 2020; 9(3). doi: 10.2217/crc-2020-0007.
- Mukherji R, Marshall J, Seeber A. Genomic Alterations and Their Implications on Survival in Nonmetastatic Colorectal Cancer: Status Quo and Future Perspectives. Cancers (Basel). 2020; 12(8): 2001. doi: 10.3390/cancers12082001
- Johnson W, Mukherji R, Kartan S, Nikbakht N, Porcu P, Alpdogan O. Allogenic Hematopoietic Stem Cell Transplantation in Advanced Stage Mycosis Fungoides and Sezary Syndrome: A Concise Review. Chinese Clinical Oncology. 2019; 8(1):12. doi 10.21037/cco.2018.10.03.
- Jain R, Savage M, Forman AD, Mukherji R, Hall, M. The Relevance of Hereditary Cancer Risks to Precision Oncology: What Should Providers Consider When Conducting Tumor Genomic Profiling. Journal of the National Comprehensive Cancer Network. 2016;14(6): 795-806. doi:10.6004/jnccn.2016.0080.
- Mukherji R, Yin C, Weinberg B, Alqahtani A, Hameed R, Barcellos A, Connole M, Pereigut C, Fortuin J, Marshall J. Continuous maintenance (Maint) capecitabine (Cape) dosing for colorectal (CRC) and pancreatic cancers (PC): A single-institution, retrospective, real-world study. Poster accepted for presentation at 2023 GI ASCO; Jan 19-21, 2023; San Francisco, California, USA.
- Mukherji R, Suguru S, Xiao J, Geng X, Wang H, Noel M, He A, Weinberg B, Marshall J, Agarwal S. Success rates and clinicopathologic associations with experimental outcomes of a novel circulating tumor cell (CTC) technology in advanced colon cancer (CC) and pancreatic cancer (PC). Poster accepted for presentation at 2023 GI ASCO; Jan 19-21, 2023; San Francisco, California, USA.
- Mukherji R, Boudriga A, Isenstein H, Marshall J. Establishing the feasibility of a patient-engagement tool to improve outpatient symptom management and dosing of patients on regorafenib. Poster presented at 2022 ASCO Quality Care Symposium; Oct 1, 2022; Chicago, IL, USA.
- Debnath D, Nair N, Mukherji R, Marshall J. A rare case of recurrent metastatic neuroendocrine adenoma of the middle ear. Poster presented at 2022 DC American College of Physicians Scientific Meeting; May 21, 2022; Washington, District of Columbia, USA.
- Alqahtani A, Alloghbi A, Yin C, Mukherji R, Weinberg B. Prognostic utility of preoperative and postoperative circulating tumor DNA (ctDNA) in resected pancreatic ductal adenocarcinoma: A systematic review and meta-analysis. Poster presented at 2022 GI ASCO; Jan 20-22, 2022; San Francisco, California, USA.
- Bauml J, Mick R, McCoach C, Weiss J, Marrone K, Nieva J, Villaruz L, Levy B, Moreno R, Mukherji R, Sun F, Schwartzman W, Shaverdashvili K, Wang X, Shah M, Woodley J, Miller N, Succe C, Ullah T, Lovly C, Doebele R, Iams W, Horn L, Dowell J, Liu G, Leighl N, Patil T, Liu S, Velcheti V, Aisner D, Camidge R. Multicenter Analysis of Mechanisms of Resistance to Osimertinib (O) in EGFR Mutated NSCLC: An ATOMIC Registry Study. Poster presented at: 2020 World Conference on Lung Cancer; Jan 28-31, 2021; Singapore.
- Shah R, Ellingsen H, Halloran M, Mukherji R, Kloo J, Lev Y. Get With the Rhythm- Telemetry Education in Internal Medicine Residency. Poster presented at: The Annual House Staff Quality Improvement and Patient Safety Poster Session; June 2018; Philadelphia, PA, USA.
- Kaczmar J, Gustafom K, Wong Y, Mukherji R, Minniti C, Sandilya V, Sprandio J, Chertock Y, Hart C, Hall M. Tumor genomic profiling (TGP) in metastatic colorectal cancer (CRC): Bridging the community and the tertiary cancer center through genomic consultation (GC). Poster Presented at: 2016 ASCO Annual Meeting; June 3-7; Chicago, IL, USA.
- Dave H, Mukherji R, Johnson S, Williams D, Jacobsohn D, Bollard C, Williams K. Voriconazole Levels Indicate That Pediatric Prophylaxis Dosing May be Insufficient. Poster Presented at: Biology of Blood and Marrow Transplantation ASPHO 2015 Annual Meeting; May 6-8, 2015; Washington, D.C.
- Gautam J, Gevaria A, Mukherji R, Bolton K. T Cell Epitope Spreading In Experimental Autoimmune Glomerulonephritis (EAG) In Rats. Poster presented at: ASN Kidney Week 2013 Annual Meeting; Nov 5-10, 2013; Atlanta, GA.